BDTX vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 17, 2026

BDTX

66.4
AI Score
VS
BDTX Wins

MRNA

44.7
AI Score

Investment Advisor Scores

BDTX

Oct 17, 2026
66score
Recommendation
HOLD

MRNA

Oct 17, 2026
45score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric BDTX MRNA Winner
Forward P/E 8.3333 23.0415 BDTX
PEG Ratio 0 0 Tie
Revenue Growth 0.0% 2.1% MRNA
Earnings Growth 0.0% -85.1% BDTX
Tradestie Score 66.4/100 44.7/100 BDTX
Profit Margin 0.0% -141.4% BDTX
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

BDTX 1M: -10.9% · 3M: -5.0% MRNA 1M: +37.9% · 3M: +266.5%

Current Technical Phase

BDTX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 37

RSI (14): 36.8 · Price: $1.72

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (57.8% over 20 days), RSI 62

RSI (14): 61.6 · Price: $218.01

Fundamentals Snapshot

Metric BDTX MRNA
Market Cap — —
Forward P/E -1.7 -45.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin — -0.7%
Operating Margin 0.0% -5.6%
EPS -0.75 -8.73
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BDTX is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.